Quantum Genomics S.A. (QNNTF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Quantum Genomics S.A. (QNNTF) trades at $0.10. Quantum Genomics S. A. is a biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases, particularly hypertension. Market cap: $6.96M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for QNNTF: QNNTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates QNNTF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
QNNTF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Quantum Genomics S.A. (QNNTF) Healthcare & Pipeline Overview
Quantum Genomics S.A. (QNNTF) is pioneering drug development in cardiovascular diseases, leveraging its unique brain aminopeptidase A inhibition platform to address hypertension and heart failure, positioning itself as a key player in the biopharmaceutical landscape.
What Is the Investment Thesis for QNNTF?
Quantum Genomics S.A. presents a compelling investment thesis driven by its innovative drug development platform and the growing demand for effective treatments for hypertension and heart failure. With firibastat in pivotal Phase III trials, the company is positioned to potentially capture a significant share of the hypertension market, which is expected to grow substantially due to the increasing prevalence of cardiovascular diseases. The global antihypertensive market is projected to reach approximately $40 billion by 2027, providing a substantial opportunity for Quantum Genomics. Additionally, the company is developing multiple candidates targeting both hypertension and heart failure, enhancing its pipeline and potential revenue streams. However, the company faces risks associated with clinical trial outcomes and regulatory approvals, which could impact its market entry and financial performance. Investors should monitor the progress of these trials closely, as successful outcomes could lead to significant stock appreciation.
Based on FMP financials and quantitative analysis
QNNTF Key Highlights
Market capitalization of $6.96M reflects the company's early-stage development phase.
- Profit margin of -88926030.0% indicates significant investment in R&D with no current revenue.
- Gross margin of -11453070.0% highlights the challenges of early-stage biopharmaceutical development.
- Beta of 0.16 suggests lower volatility compared to the broader market, indicating stability in uncertain times.
- No dividend yield as the company reinvests in drug development rather than returning capital to shareholders.
Who Are QNNTF's Competitors?
QNNTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PFE Pfizer Inc. | $28.24 | +3.63% | $161B | 67 |
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| AZN AstraZeneca PLC | $164.95 | +3.03% | $256B | 61 |
| JNJ Johnson & Johnson | $267.37 | -2.21% | $644B | 90 |
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +5.06% | $7.16M | 72 |
| RLYB Rallybio Corporation | $17.00 | +1.37% | $90.2M | 81 |
| ICCC ImmuCell Corporation | $10.13 | +3.79% | $91.6M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QNNTF's Key Strengths?
Innovative drug development platform targeting unmet medical needs.
- Strong focus on cardiovascular diseases, a growing market.
- Experienced leadership in biopharmaceutical development.
- Unique mechanism of action with brain aminopeptidase A inhibition.
What Are QNNTF's Weaknesses?
Limited financial resources due to early-stage development.
- Small team size may limit operational capabilities.
- High dependency on successful clinical trial outcomes.
- Negative profit and gross margins indicate financial challenges.
What Could Drive QNNTF Stock Higher?
Completion of pivotal Phase III trials for firibastat, expected in late 2026.
- Active clinical trials for QGC011, QGC006, and QGC606 targeting hypertension and heart failure.
- Potential announcements regarding partnerships or collaborations to enhance development capabilities.
- Continued research and development efforts to expand the product pipeline.
- Anticipated regulatory filings for firibastat pending successful trial outcomes.
What Are the Key Risks for QNNTF?
Regulatory challenges that may delay product approvals.
- Financial constraints due to negative profit margins and limited revenue.
- Competition from established pharmaceutical companies with more resources.
- Risks associated with clinical trial failures impacting product viability.
What Are the Growth Opportunities for QNNTF?
- Growth opportunity 1: The global hypertension market is projected to reach $40 billion by 2027, driven by the increasing prevalence of high blood pressure. Quantum Genomics' lead product, firibastat, targets this market with a novel mechanism of action, potentially offering a new treatment option for millions of patients. The successful completion of Phase III trials could position the company to capture a significant share of this growing market within the next few years.
- Growth opportunity 2: The development of QGC011, aimed at combination therapy for hypertension, represents a strategic move to address the complex needs of patients who require multiple medications. As the market shifts towards personalized medicine, this product could tap into a growing segment of patients seeking effective combination therapies. The anticipated launch could coincide with the expected market growth, enhancing revenue potential.
- Growth opportunity 3: The increasing focus on heart failure treatment presents an additional avenue for growth. With firibastat also in clinical trials for heart failure, Quantum Genomics could leverage this dual indication to broaden its market reach. The heart failure market is expected to grow significantly, providing a substantial opportunity for the company to establish itself as a leader in this therapeutic area.
- Growth opportunity 4: Strategic partnerships with larger pharmaceutical companies could enhance Quantum Genomics' development capabilities and market access. Collaborations may provide additional resources for clinical trials and commercialization efforts, accelerating the timeline for bringing products to market. Such partnerships could also mitigate financial risks associated with drug development.
- Growth opportunity 5: The increasing emphasis on innovative drug delivery systems and personalized medicine aligns with Quantum Genomics' research focus. By leveraging advancements in biotechnology and patient-centric approaches, the company can enhance the efficacy and safety profiles of its products, potentially leading to improved patient outcomes and market acceptance.
What Are QNNTF's Competitive Advantages?
- Unique focus on brain aminopeptidase A inhibition offers a differentiated approach to treatment.
- Strong pipeline of drug candidates targeting both hypertension and heart failure.
- Commitment to addressing significant unmet medical needs in cardiovascular health.
- Potential for strategic partnerships to enhance development and market access.
- Small team allows for agile decision-making and focused research efforts.
What Does QNNTF Do?
Quantum Genomics S.A., founded in 2005 and headquartered in Paris, France, is a biopharmaceutical company that specializes in developing innovative drugs aimed at treating cardiovascular diseases. The company has established a unique platform based on brain aminopeptidase A inhibition (BAPAI), which primarily targets conditions such as high blood pressure and heart failure. Quantum Genomics is advancing its lead product, firibastat, a monotherapy currently undergoing pivotal Phase III trials for hypertension and additional clinical trials for heart failure. Alongside firibastat, the company is also developing QGC011, aimed at hypertension through combination therapy, and QGC006 and QGC606, which target both hypertension and heart failure. Despite its small size, with only three employees, Quantum Genomics is focused on addressing significant unmet medical needs in the cardiovascular sector, which is characterized by a growing prevalence of hypertension and heart-related conditions. The company’s innovative approach and commitment to research position it as a potential leader in this niche market, with ongoing developments that could significantly impact patient care in cardiovascular health.
What Products and Services Does QNNTF Offer?
- Develops innovative drugs for cardiovascular diseases.
- Focuses on brain aminopeptidase A inhibition for treating hypertension.
- Conducts clinical trials for firibastat, targeting hypertension and heart failure.
- Explores combination therapies with QGC011 for enhanced treatment efficacy.
- Engages in research and development to address unmet medical needs.
- Operates primarily in the biopharmaceutical sector with a focus on cardiovascular health.
How Does QNNTF Make Money?
- Generates revenue through the development and commercialization of pharmaceutical products.
- Focuses on innovative drug development to meet unmet medical needs.
- Engages in clinical trials to validate the efficacy and safety of drug candidates.
- Potential partnerships and collaborations with larger pharmaceutical firms for market access.
- Plans to monetize products through sales in the growing cardiovascular market.
What Industry Does QNNTF Operate In?
The biotechnology industry, particularly in the cardiovascular sector, is witnessing significant growth driven by an aging population and increasing prevalence of chronic diseases such as hypertension and heart failure. With the global antihypertensive market projected to expand, innovative companies like Quantum Genomics are well-positioned to capitalize on this trend. The competitive landscape includes major pharmaceutical companies and emerging biotechs, all vying for market share in a space that demands effective and novel treatment options. Quantum Genomics' unique approach to targeting brain aminopeptidase A inhibition sets it apart from traditional therapies, potentially offering a competitive advantage in addressing unmet medical needs.
Who Are QNNTF's Key Customers?
- Healthcare providers seeking effective treatments for hypertension and heart failure.
- Patients suffering from cardiovascular diseases requiring innovative therapies.
- Pharmaceutical partners interested in collaboration for drug development.
- Investors looking for opportunities in the biopharmaceutical sector.
- Regulatory bodies assessing the safety and efficacy of new drug applications.
Key Financial Metrics
Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -176.9%, the inverse of the P/E and a quick read on earnings relative to price.
Quantum Genomics S.A. (QNNTF) Valuation Context
Valued at $6.96M, QNNTF is classified as a micro-cap stock.
Company Profile
Quantum Genomics S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Paris, FR. The company is led by CEO Mathieu Bigois. QNNTF has traded publicly since 2021.
Financial Health
Quantum Genomics S.A.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Forward Outlook
Wall Street analysts project Quantum Genomics S.A. revenue of about $158.3M for fiscal 2026, with EPS near $5.93.
QNNTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Innovative drug development platform targeting unmet medical needs.
- Strong focus on cardiovascular diseases, a growing market.
- Experienced leadership in biopharmaceutical development.
- Unique mechanism of action with brain aminopeptidase A inhibition.
Bear Case
- Limited financial resources due to early-stage development.
- Small team size may limit operational capabilities.
- High dependency on successful clinical trial outcomes.
- Negative profit and gross margins indicate financial challenges.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
QNNTF Latest News
No recent news available for QNNTF.
QNNTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QNNTF.
Price Targets
Wall Street price target analysis for QNNTF.
QNNTF MoonshotScore
What does this score mean?
The MoonshotScore rates QNNTF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Mathieu Bigois
CEO
Mathieu Bigois has been at the helm of Quantum Genomics S.A. since its inception in 2005. With a background in biopharmaceuticals and extensive experience in drug development, he has led the company through various stages of growth and research. His expertise lies in navigating the complexities of clinical trials and regulatory processes, ensuring that the company remains focused on its mission to develop innovative therapies for cardiovascular diseases.
Track Record: Under Mathieu Bigois' leadership, Quantum Genomics has successfully advanced its lead product, firibastat, into pivotal Phase III trials. His strategic vision has been instrumental in shaping the company's research focus and establishing its unique position in the biopharmaceutical landscape.
QNNTF OTC Market Information
The OTC Other tier includes companies that trade over-the-counter but do not meet the requirements for the higher tiers like OTCQX or OTCQB. This tier typically features smaller companies with less stringent reporting requirements, which may impact transparency and investor information.
- OTC Tier: OTC Other
- Limited financial transparency due to lower reporting standards.
- Potential for lower liquidity compared to stocks on major exchanges.
- Higher volatility associated with smaller OTC companies.
- Regulatory risks related to drug development and approvals.
- Verify the company's clinical trial progress and outcomes.
- Assess the management team's experience and track record.
- Review any available financial disclosures or reports.
- Monitor regulatory developments affecting the company's products.
- Evaluate the competitive landscape and market positioning.
- Established presence in the biopharmaceutical sector since 2005.
- Ongoing clinical trials for lead product firibastat.
- Engagement with regulatory bodies for drug approvals.
- Focus on addressing significant unmet medical needs.
What Investors Ask About Quantum Genomics S.A. (QNNTF) — Healthcare
What does Quantum Genomics S.A. do?
Quantum Genomics S.A. is a biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases, particularly hypertension and heart failure. The company utilizes a unique platform based on brain aminopeptidase A inhibition to create drugs like firibastat, which is currently in pivotal Phase III trials. Additionally, Quantum Genomics is exploring combination therapies and other drug candidates to address significant unmet medical needs in this sector.
What are the main risks for QNNTF?
Quantum Genomics S.A. faces several risks, including regulatory challenges that could delay or prevent product approvals, particularly for its lead candidate firibastat. Financial constraints are also a concern, as the company currently operates with negative profit margins and limited revenue. Furthermore, competition from established pharmaceutical companies poses a threat, as they have more resources and established market presence.
How does Quantum Genomics S.A. navigate regulatory approval processes?
Quantum Genomics S.A. navigates regulatory approval processes by adhering to stringent guidelines set forth by agencies such as the FDA and EMA. The company focuses on conducting robust clinical trials to demonstrate the safety and efficacy of its drug candidates, particularly firibastat. Engaging with regulatory bodies throughout the development process helps ensure compliance and facilitates smoother review timelines.
What are the key factors to evaluate for QNNTF?
Evaluate QNNTF on fundamentals, analyst consensus, and risk factors. Quantum Genomics S.A. presents a compelling investment thesis driven by its innovative drug development platform and the growing demand for effective treatments for hypertension and heart failure. Not financial advice.
How frequently does QNNTF data refresh on this page?
QNNTF's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven QNNTF's recent stock price performance?
Quantum Genomics S.A. (QNNTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug development platform targeting unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider QNNTF overvalued or undervalued right now?
Quantum Genomics S.A. (QNNTF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research QNNTF before investing?
Before investing in Quantum Genomics S.A. (QNNTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of June 2026.